Mirati Therapeutics - MRTX Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $60.00
Forecasted Upside: 2.21%
Number of Analysts: 14
Breakdown:
0 Sell Ratings
11 Hold Ratings
3 Buy Ratings
0 Strong Buy Ratings

^$58.70 As of 01/23/2024 01:00 AM ET

+0 (0.00%)

Get New Mirati Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for MRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRTX

^$60.00

▲ +2.21% Upside Potential

This price target is based on 14 analysts offering 12 month price targets for Mirati Therapeutics in the last 3 months. The average price target is $60.00, with a high forecast of $82.00 and a low forecast of $37.00. The average price target represents a 2.21% upside from the last price of $58.70.

Current Consensus is Hold

The current consensus among 14 polled investment analysts is to hold stock in Mirati Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
11 hold ratings
0 sell ratings

Ratings as of

10/25/2022

0 strong buy ratings
3 buy ratings
11 hold ratings
0 sell ratings

Ratings as of

1/23/2023

0 strong buy ratings
3 buy ratings
11 hold ratings
0 sell ratings

Ratings as of

4/23/2023

0 strong buy ratings
3 buy ratings
11 hold ratings
0 sell ratings

Ratings as of

7/22/2023

0 strong buy ratings
3 buy ratings
11 hold ratings
0 sell ratings

Ratings as of

10/20/2023

0 strong buy ratings
3 buy ratings
11 hold ratings
0 sell ratings

Ratings as of

1/18/2024

0 strong buy ratings
3 buy ratings
11 hold ratings
0 sell ratings

Ratings as of

3/18/2024

0 strong buy ratings
3 buy ratings
11 hold ratings
0 sell ratings

Ratings as of

4/17/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
12/20/2023	Citigroup	Reiterated Rating	Buy ➝ Neutral	$48.00 ➝ $59.00	Low
11/7/2023	Leerink Partnrs	Downgrade	Outperform ➝ Market Perform		Low
11/7/2023	SVB Leerink	Reiterated Rating	Outperform ➝ Market Perform	$78.00 ➝ $58.00	Low
11/7/2023	Stifel Nicolaus	Reiterated Rating	Buy ➝ Hold	$83.00 ➝ $59.00	Low
10/9/2023	Piper Sandler	Downgrade	Overweight ➝ Neutral	$58.00	Low
10/9/2023	B. Riley	Downgrade	Buy ➝ Neutral	$65.00 ➝ $60.00	Low
10/9/2023	Scotiabank	Upgrade	Underperform ➝ Sector Perform	$58.00	Low
10/9/2023	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$55.00 ➝ $58.00	Low
10/9/2023	JMP Securities	Downgrade	Outperform ➝ Market Perform		Low
10/6/2023	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$83.00	Low
10/6/2023	BMO Capital Markets	Boost Target	Market Perform ➝ Market Perform	$31.00 ➝ $72.00	Low
10/6/2023	JMP Securities	Boost Target	Market Outperform ➝ Market Outperform	$58.00 ➝ $82.00	Low
9/28/2023	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$58.00	Low
8/10/2023	Citigroup	Upgrade	Neutral ➝ Buy	$51.00 ➝ $48.00	Low
8/9/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $37.00	Low
8/9/2023	Piper Sandler	Initiated Coverage	Overweight	$45.00	Low
8/9/2023	BMO Capital Markets	Lower Target	Market Perform ➝ Market Perform	$40.00 ➝ $31.00	Low
8/9/2023	Stifel Nicolaus	Boost Target		$77.00 ➝ $83.00	Low
8/9/2023	B. Riley	Upgrade	Neutral ➝ Buy	$45.00	Low
8/9/2023	Oppenheimer	Boost Target	Outperform ➝ Outperform	$56.00 ➝ $62.00	Low
7/27/2023	Scotiabank	Initiated Coverage	Underperform		Low
7/24/2023	Guggenheim	Lower Target	Buy	$104.00 ➝ $60.00	Low
7/24/2023	B. Riley	Lower Target	Neutral	$51.00 ➝ $45.00	Low
7/24/2023	Bank of America	Lower Target		$54.00 ➝ $46.00	Low
7/24/2023	Barclays	Lower Target	Overweight	$75.00 ➝ $71.00	Low
7/14/2023	Morgan Stanley	Lower Target	Equal Weight	$51.00 ➝ $42.00	Low
5/25/2023	Oppenheimer	Upgrade	Market Perform ➝ Outperform		Low
5/25/2023	BMO Capital Markets	Lower Target		$50.00 ➝ $40.00	Low
5/25/2023	Barclays	Lower Target		$90.00 ➝ $75.00	Low
5/11/2023	VNET Group	Reiterated Rating	Maintains		Low
5/11/2023	22nd Century Group	Reiterated Rating	Reiterates		Low
5/10/2023	Stifel Nicolaus	Lower Target		$78.00 ➝ $77.00	Low
3/1/2023	BMO Capital Markets	Lower Target	Market Perform	$59.00 ➝ $50.00	Low
1/27/2023	Morgan Stanley	Lower Target	Equal Weight	$60.00 ➝ $50.00	Low
1/23/2023	B. Riley	Boost Target	Neutral	$52.00 ➝ $56.00	Low
12/14/2022	Morgan Stanley	Lower Target	Equal Weight	$70.00 ➝ $60.00	Low
12/14/2022	SVB Leerink	Lower Target	Outperform	$85.00 ➝ $75.00	Low
12/14/2022	Needham & Company LLC	Initiated Coverage	Hold		Low
12/14/2022	Barclays	Lower Target		$169.00 ➝ $90.00	N/A
12/13/2022	Piper Sandler	Boost Target		$84.00 ➝ $87.00	Low
12/9/2022	Stifel Nicolaus	Lower Target		$73.00	Low
12/9/2022	Citigroup	Downgrade	Buy ➝ Neutral	$121.00 ➝ $53.00	Low
12/8/2022	SVB Leerink	Lower Target	Outperform	$102.00 ➝ $85.00	Low
12/8/2022	Bank of America	Lower Target		$100.00 ➝ $61.00	Low
12/8/2022	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$110.00 ➝ $59.00	Low
12/8/2022	Piper Sandler	Lower Target	Overweight	$110.00 ➝ $84.00	Low
12/8/2022	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$94.00 ➝ $65.00	Low
12/8/2022	Oppenheimer	Lower Target	Market Perform	$85.00 ➝ $60.00	Low
11/16/2022	Citigroup	Lower Target	Buy	$127.00 ➝ $121.00	Low
11/9/2022	SVB Leerink	Lower Target	Outperform	$111.00 ➝ $102.00	Low
10/28/2022	B. Riley	Initiated Coverage	Neutral	$72.00	Low
9/26/2022	JPMorgan Chase & Co.	Lower Target	Overweight	$109.00 ➝ $94.00	Low
9/15/2022	Piper Sandler	Initiated Coverage	Overweight	$110.00	Low
9/13/2022	Jonestrading	Initiated Coverage	Buy	$100.00	Low
8/4/2022	JMP Securities	Boost Target	Market Outperform	$72.00 ➝ $90.00	Low
7/7/2022	Citigroup	Lower Target	Buy	$208.00 ➝ $127.00	N/A
6/9/2022	Oppenheimer	Lower Target		$85.00	Low
6/7/2022	BMO Capital Markets	Reiterated Rating	Buy	$80.00	High
6/7/2022	The Goldman Sachs Group	Lower Target	Buy	$216.00 ➝ $188.00	High
6/7/2022	Stifel Nicolaus	Boost Target		$105.00 ➝ $111.00	High
6/7/2022	JMP Securities	Upgrade	Market Perform ➝ Outperform	$72.00	High
6/4/2022	Jonestrading	Reiterated Rating	Buy	$100.00	Low
5/27/2022	SVB Leerink	Lower Target	Outperform	$164.00 ➝ $111.00	High
5/24/2022	The Goldman Sachs Group	Lower Target	Buy	$253.00 ➝ $216.00	Low
5/20/2022	Guggenheim	Upgrade	Neutral ➝ Buy	$115.00	High
5/5/2022	Citigroup	Lower Target		$227.00 ➝ $208.00	High
3/2/2022	Citigroup	Lower Target	Buy	$244.00 ➝ $227.00	Medium
3/1/2022	Stifel Nicolaus	Lower Target	Buy	$150.00 ➝ $118.00	Low
3/1/2022	Morgan Stanley	Lower Target	Equal Weight	$150.00 ➝ $140.00	Low
3/1/2022	BMO Capital Markets	Lower Target		$187.00 ➝ $130.00	High
2/18/2022	Oppenheimer	Lower Target		$175.00 ➝ $155.00	Low
2/8/2022	SVB Leerink	Reiterated Rating	Outperform		High
2/1/2022	Morgan Stanley	Lower Target	Equal Weight	$175.00 ➝ $150.00	Low
2/1/2022	Bank of America	Upgrade	Underperform ➝ Neutral	$171.00 ➝ $141.00	High
11/18/2021	BMO Capital Markets	Initiated Coverage	Outperform	$187.00	Low
9/22/2021	Stifel Nicolaus	Initiated Coverage	Buy	$202.00	Medium
9/22/2021	Citigroup	Boost Target	Buy	$232.00 ➝ $244.00	Low
9/21/2021	Morgan Stanley	Boost Target	Equal Weight	$160.00 ➝ $173.00	High
9/21/2021	SVB Leerink	Boost Target	Outperform	$195.00 ➝ $205.00	High
9/21/2021	Oppenheimer	Boost Target	Market Perform	$160.00 ➝ $175.00	High
9/20/2021	Jefferies Financial Group	Initiated Coverage	Buy	$193.00	High
9/19/2021	SVB Leerink	Reiterated Rating	Buy		High
9/7/2021	JPMorgan Chase & Co.	Lower Target	Overweight	$205.00 ➝ $203.00	Low
8/26/2021	Morgan Stanley	Initiated Coverage	Equal Weight	$160.00	High
8/9/2021	HC Wainwright	Lower Target	Buy	$251.00 ➝ $247.00	High
6/4/2021	Citigroup	Upgrade	Neutral ➝ Buy		Low
5/24/2021	Oppenheimer	Reiterated Rating	Outperform ➝ Market Perform	$245.00 ➝ $160.00	Medium
5/17/2021	Oppenheimer	Downgrade	Outperform ➝ Market Perform	$245.00 ➝ $160.00	Low
5/10/2021	HC Wainwright	Lower Target	Buy	$255.00 ➝ $251.00	Medium
5/10/2021	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$208.00 ➝ $196.00	Medium
3/1/2021	Oppenheimer	Lower Target	Outperform	$260.00 ➝ $255.00	Low
3/1/2021	HC Wainwright	Lower Target	Buy	$257.00 ➝ $255.00	Low
1/15/2021	HC Wainwright	Lower Target	Buy	$265.00 ➝ $257.00	Low
12/16/2020	Credit Suisse Group	Boost Target	Outperform	$225.00 ➝ $285.00	Low
12/8/2020	Evercore ISI	Initiated Coverage	Outperform		Medium
12/8/2020	JMP Securities	Initiated Coverage	Market Perform		Medium
11/17/2020	Bank of America	Downgrade	Neutral ➝ Underperform	$196.00	Low
11/10/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$206.00 ➝ $208.00	Low
11/10/2020	Guggenheim	Downgrade	Buy ➝ Neutral	$230.00	Low
11/9/2020	HC Wainwright	Boost Target	Buy	$233.00 ➝ $265.00	Medium
11/5/2020	Oppenheimer	Boost Target		$225.00 ➝ $260.00	Low
11/5/2020	Piper Sandler	Boost Target	Overweight	$210.00 ➝ $260.00	Medium
11/2/2020	HC Wainwright	Lower Target	Buy	$238.00 ➝ $233.00	Low
10/29/2020	Barclays	Boost Target	Overweight	$143.00 ➝ $244.00	High
10/27/2020	Credit Suisse Group	Boost Target	Outperform	$190.00 ➝ $225.00	High
10/26/2020	Oppenheimer	Boost Target	Outperform	$190.00 ➝ $225.00	High
10/26/2020	SVB Leerink	Boost Target	Outperform	$134.00 ➝ $195.00	High
10/26/2020	The Goldman Sachs Group	Boost Target	Buy	$152.00 ➝ $267.00	High
10/26/2020	HC Wainwright	Boost Target	Buy	$222.00 ➝ $238.00	High
10/26/2020	Piper Sandler	Boost Target	Overweight	$170.00 ➝ $210.00	High
10/21/2020	BMO Capital Markets	Boost Target	Market Perform	$101.00 ➝ $176.00	High
10/16/2020	HC Wainwright	Boost Target	Buy	$185.00 ➝ $222.00	High
10/8/2020	CSFB	Boost Target	Outperform	$140.00 ➝ $190.00	Medium
10/8/2020	Credit Suisse Group	Boost Target	Outperform	$140.00 ➝ $190.00	Medium
9/28/2020	Bank of America	Initiated Coverage	Neutral	$172.00	Low
9/21/2020	Oppenheimer	Boost Target	Outperform	$133.00 ➝ $190.00	Low
9/21/2020	Piper Sandler	Boost Target	Overweight	$145.00 ➝ $170.00	Low
9/18/2020	Citigroup	Downgrade	Buy ➝ Neutral	$127.00 ➝ $183.00	Medium
9/17/2020	HC Wainwright	Boost Target	Buy	$163.00 ➝ $185.00	High
8/10/2020	Oppenheimer	Boost Target		$105.00 ➝ $133.00	Medium
8/10/2020	HC Wainwright	Reiterated Rating	Buy	$163.00	Medium
8/7/2020	Credit Suisse Group	Boost Target	Outperform	$135.00 ➝ $140.00	Medium
8/7/2020	Barclays	Boost Target	Overweight	$123.00 ➝ $143.00	Medium
7/29/2020	Credit Suisse Group	Boost Target	Outperform	$115.00 ➝ $135.00	Medium
5/1/2020	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$116.00	High
4/16/2020	The Goldman Sachs Group	Initiated Coverage	Buy	$151.00	High
3/30/2020	Oppenheimer	Lower Target	Outperform	$129.00 ➝ $105.00	High
3/12/2020	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral	$88.00	High
2/28/2020	HC Wainwright	Reiterated Rating	Buy	$134.00 ➝ $126.00	High
1/27/2020	BMO Capital Markets	Initiated Coverage	Market Perform	$101.00	Low
1/24/2020	HC Wainwright	Reiterated Rating	Buy	$117.00 ➝ $134.00	Medium
1/7/2020	Cowen	Reiterated Rating	Buy		High
11/5/2019	Guggenheim	Boost Target	Buy	$116.00 ➝ $128.00	Low
10/29/2019	Cantor Fitzgerald	Boost Target	Neutral	$81.00 ➝ $85.00	High
10/18/2019	Cowen	Reiterated Rating	Buy		Low
10/17/2019	HC Wainwright	Reiterated Rating	Buy		High
10/9/2019	Citigroup	Set Target	Buy	$130.00	Low
9/27/2019	Credit Suisse Group	Set Target	Positive ➝ Buy	$120.00 ➝ $115.00	Low
9/24/2019	Guggenheim	Upgrade	Neutral ➝ Buy	$116.00	High
9/11/2019	B. Riley	Lower Target	Neutral	$92.00 ➝ $83.00	High
9/9/2019	Cantor Fitzgerald	Lower Target	Neutral	$85.00 ➝ $81.00	High
9/9/2019	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$89.00 ➝ $105.00	Medium
8/6/2019	HC Wainwright	Reiterated Rating	Buy	$117.00	High
8/6/2019	Cowen	Reiterated Rating	Buy		High
8/2/2019	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$101.00 ➝ $85.00	High
7/31/2019	SVB Leerink	Set Target	Buy	$118.00	High
7/18/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Hold ➝ Hold	$86.00	Medium
7/12/2019	JPMorgan Chase & Co.	Boost Target	Neutral	$70.00 ➝ $101.00	Low
6/19/2019	B. Riley	Downgrade	Buy ➝ Neutral	$60.00 ➝ $92.00	Medium
6/7/2019	Guggenheim	Downgrade	Buy ➝ Neutral	$95.56	Medium
6/5/2019	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $117.00	Low
6/5/2019	Barclays	Boost Target	Overweight	$85.00 ➝ $123.00	Low
6/4/2019	SunTrust Banks	Boost Target	Buy	$120.00	Medium
6/4/2019	Piper Sandler Companies	Boost Target	Overweight	$85.00 ➝ $125.00	Medium
6/4/2019	Cowen	Reiterated Rating	Buy		High
6/4/2019	Cantor Fitzgerald	Boost Target	Neutral ➝ Positive	$66.00 ➝ $85.00	High
6/4/2019	Citigroup	Upgrade	Neutral ➝ Buy	$76.00 ➝ $132.00	High
5/16/2019	Cantor Fitzgerald	Reiterated Rating	Hold		High
5/15/2019	Cowen	Reiterated Rating	Buy		High
5/1/2019	Cantor Fitzgerald	Reiterated Rating	Hold	$66.00	High

(Data available from 4/18/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

6 very positive mentions
8 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/21/2023

5 very positive mentions
18 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

10/21/2023

0 very positive mentions
11 positive mentions
0 negative mentions
2 very negative mentions

Mentions as of

11/20/2023

4 very positive mentions
3 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/20/2023

8 very positive mentions
7 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

1/19/2024

1 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/18/2024

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/19/2024

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/18/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

No positive mentions tracked during this time.

Very Positive

No very positive mentions tracked during this time.

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Today's Range

Now: $58.70

$58.70

50 Day Range

MA: $58.82

$58.70

$59.28

52 Week Range

Now: $58.70

$27.30

$64.41

Volume

N/A

Average Volume

2,758,857 shs

Market Capitalization

$4.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Mirati Therapeutics?: The following Wall Street analysts have issued research reports on Mirati Therapeutics in the last twelve months: 22nd Century Group, Inc., B. Riley, Bank of America Co., Barclays PLC, BMO Capital Markets, Citigroup Inc., Guggenheim, Jefferies Financial Group Inc., JMP Securities, Leerink Partnrs, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Scotiabank, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, and VNET Group, Inc..
View the latest analyst ratings for MRTX.
What is the current price target for Mirati Therapeutics?: 14 Wall Street analysts have set twelve-month price targets for Mirati Therapeutics in the last year. Their average twelve-month price target is $60.00, suggesting a possible upside of 2.2%. JMP Securities has the highest price target set, predicting MRTX will reach $82.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $37.00 for Mirati Therapeutics in the next year.
View the latest price targets for MRTX.
What is the current consensus analyst rating for Mirati Therapeutics?: Mirati Therapeutics currently has 11 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MRTX, but not buy more shares or sell existing shares.
View the latest ratings for MRTX.
What other companies compete with Mirati Therapeutics?: Other companies that are similar to Mirati Therapeutics include Nuvalent, Perrigo, Alkermes, Alpine Immune Sciences and Insmed. Learn More about companies similar to Mirati Therapeutics.
How do I contact Mirati Therapeutics' investor relations team?: Mirati Therapeutics' physical mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 332-3410 and its investor relations email address is [email protected]. The official website for Mirati Therapeutics is www.mirati.com. Learn More about contacing Mirati Therapeutics investor relations.

Mirati Therapeutics - MRTX Stock Price Target and Predictions

Analyst Price Target for MRTX

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Mirati Therapeutics?

What is the current price target for Mirati Therapeutics?

What is the current consensus analyst rating for Mirati Therapeutics?

What other companies compete with Mirati Therapeutics?

How do I contact Mirati Therapeutics' investor relations team?